• Online database allows clinicians and patients to search for genetic and genomic tests by disease state
  • Increases access to information about and awareness of Cancer Genetics' proprietary diagnostic tests

RUTHERFORD, N.J., Aug. 27, 2014 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company"), an emerging leader in DNA-based cancer diagnostics, announced today that the National Institutes of Health's (NIH) Genetic Testing Registry now features the company's proprietary diagnostic and prognostic genomic tests. The GTR is a searchable online registry of genetic tests and provides clinicians and patients with information about each test's purpose, methodology, validity, usefulness, and credentials. CGI's presence on the Genetic Testing Registry extends access to information about the company's proprietary genomic tests and extensive non-proprietary test offerings to an even broader audience of clinicians, oncologists, patients, and biopharma companies.

"Having information about our tests widely available via an online database is crucial to ensuring patients, clinicians, and health care providers have the information they need about our genomic cancer tests and panels," said Panna Sharma, CEO of Cancer Genetics, Inc. "We want to drive greater adoption of our proprietary tests for lymphomas and leukemias, kidney cancer, and HPV-associated cancers. Participating in the Genetic Testing Registry helps us move towards this important objective."

"We are very pleased to add Cancer Genetics, Inc.'s test menu to GTR as part of our new offerings on cancer tests," said Wendy Rubinstein, M.D., Ph.D., Director of the Genetic Testing Registry and Senior Scientist at the National Center for Biotechnology Information, a division of the National Library of Medicine at the National Institutes of Health. "Our goal is to improve transparency surrounding genetic and genomic tests and to improve access to information for health care providers, researchers, and others. Cancer Genetics is an early adopter among laboratories offering testing for malignancies and their data submission helps us achieve these goals."

CGI's proprietary genomic tests, which are CLIA and New York State licensed, can diagnose, sub-type, and prognose a number of difficult to diagnose cancers. These tests provide critical information to guide clinicians in the clinical management of their patients, and are used by the company's biopharma customers for selection and stratification of clinical trial participants. The company's portfolio of proprietary tests listed on the registry includes:

  • FHACT®, CGI's fish based HPV-associated cancer test, which is currently available for cervical cancer and detects genomic abnormalities associated with progression to cancer.
  • UroGenRA®-Kidney, a CGH-microarray test that can diagnose and subtype renal cell carcinoma and may reduce unnecessary nephrectomy for benign tumors.
  • MatBA®, CGI's panel for mature B-cell neoplasms. MatBA® is currently available for chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma.

Cancer Genetics' GTR listings includes forty tests in total. The company's GTR listing can be found at http://www.ncbi.nlm.nih.gov/gtr/labs/504922/. For more information about the NIH Genetic Testing Registry, visit www.ncbi.nlm.nih.gov/gtr.

About Cancer Genetics

Cancer Genetics Inc. (Nasdaq:CGIX) is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital, and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Our state-of-the-art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute.

For further information, please see http://www.cancergenetics.com.

Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that the transaction will not close or, if it closes, will not realize the currently anticipated benefits, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company's Form 10-K for the year ended December 31, 2013 and 10-Q for the quarter ended March 31, 2014 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.
CONTACT: Media Relations         Paul Kuntz         RedChip Companies, Inc.         800-733-2447, ext. 105         paul@redchip.com                  Investor Relations         Michael Rice         LifeSci Advisors, LLC         646-597-6997